Biomarker Discovery Services

The SERA platform has features that make it robust for biomarker discovery.


Identification of validated and novel biomarkers in infectious disease, cancer, and autoimmunity

Potential for development of biomarkers/panels for early disease detection, sub-types, response to therapy, disease monitoring

Large random library

  • Ability to identify high affinity epitopes and peptides for porting content
  • Ability to discover epitopes in multiple organisms in the same assay
  • Ability to look for signal against new strains and to predict for reactivity against new variants in existing cases

Robust assay and QA/QC

  • Ability to compare large numbers of disease samples to explore epitope diversity and immune response sub-types
  • Ability to compare before-and after signals for changes in repertoire at the epitope and antigen levels

Large database of non-disease controls

  • Only a modest number (20-30) of disease samples are required for initial discovery

How it Works

Customer Provides:

50 ul of serum or plasma per sample.

Minimal information about the samples.

Serimmune analyzes each sample for IgG antibodies using its 10 billion member, random 12mer, bacterial peptide display library.

Serimmune performs epitope analysis across the entire proteome using its proprietary IMUNE and PIWAS methodologies.

Serimmune provides summary data and visualizations for each sample, including raw data for subsequent customer analysis.

Sample Requirements


Serum, Plasma and CSF


100ul for Serum or Plasma, 150ul for CSF


Any species with antibodies that are able to bind A/G beads


Samples may be stored for up to 2 weeks at 2-8°C or indefinitely if frozen


Samples may be shipped overnight at ambient temperature
or shipped on wet ice. Blood or serum/plasma samples should be shipped in biohazardous material compliant packaging

Custom assays available upon request